Sort
21,453 grants matching “tuberculosis”
Diagnostic Innovations for Pediatric Tuberculosis in Bolivia
$570,008Richard A Oberhelman · Tulane University Of Louisiana · R01 · FY2025 · AI
Tulane National Primate Research Center
$569,964Lee Hamm · Tulane University Of Louisiana · P51 · FY2014 · OD
Memory, Phenotype, and Function of TB-reactive Human MR1 Restricted T cells
$569,907David M. Lewinsohn · Oregon Health & Science University · R01 · FY2021 · AI
Central Africa International Epidemiology databases to Evaluate AIDS
$569,780Marcel Yotebieng · Albert Einstein College Of Medicine · U01 · FY2025 · AI
Phage mimicry of mycobacterial signaling
$569,693Graham F. Hatfull · University Of Pittsburgh At Pittsburgh · R01 · FY2010 · AI
Conduits and Control of KatG Intramolecular Electron Transfer: Formation and Operation of a Novel Cofactor
$569,460Douglas C Goodwin · Auburn University · · FY2016 · BIO
Phage mimicry of mycobacterial signaling
$569,345Graham F. Hatfull · University Of Pittsburgh At Pittsburgh · R01 · FY2006 · AI
Technology Core: Sequencing
$569,304Thomas R Ioerger · Harvard School Of Public Health · U19 · FY2017 · AI
US BRAZIL COLLABORATION ON IMMUNITY AND BIOMARKERS IN TUBERCULOSIS
$569,292Jerrold J. Ellner · Boston Medical Center · U01 · FY2013 · AI
Biotin synthesis and biotin ligation in Mtb
$569,199Dirk Schnappinger · Weill Medical Coll Of Cornell Univ · R01 · FY2013 · AI
PREVINE-TB: PRevent: EValuating the implementation of NEw strategies for preventive TB among people living with HIV in Brazil
$569,023Jonathan E Golub · Johns Hopkins University · R01 · FY2021 · AI
Drug tourism to Mexico: Impact of Mexicos new drug law on HIV-HCV-TB in US IDUs
$568,934Richard S Garfein · University Of California, San Diego · R01 · FY2015 · DA
Drug tolerance, bacterial heterogeneity and adverse TB treatment outcomes
$568,737David R Sherman · Rbhs-New Jersey Medical School · U19 · FY2021 · AI
CaO-heated DNA amplification obviates electricity requirement at point of care
$568,735Paul D. Labarre · Path · R01 · FY2012 · EB
OPTIMIZING HIV/TB MANAGEMENT IN THE HAART ERA
$568,512Gail Shor-Posner · University Of Miami School Of Medicine · D43 · FY2008 · TW
HIV/TB Prevention and Treatment in the HAART ERA
$568,512Gail Shor-Posner · University Of Miami School Of Medicine · D43 · FY2007 · TW
Prevent TB: Application of choice architecture to implement TB preventive therapy in South Africa
$568,143Christopher J Hoffmann · Johns Hopkins University · R01 · FY2023 · AI
Mechanisms of anti-fungal Vaccine immunity
$568,031Bruce Steven Klein · University Of Wisconsin-Madison · R01 · FY2017 · AI
Mechanisms of anti-fungal Vaccine immunity
$568,031Bruce Steven Klein · University Of Wisconsin-Madison · R01 · FY2015 · AI
Mechanisms of anti-fungal Vaccine immunity
$568,031Bruce Steven Klein · University Of Wisconsin-Madison · R01 · FY2016 · AI
Genetic Requirements for the survival of Tubercle Bacilli in Nonhuman Primates
$567,851Deepak Kaushal · Tulane University Of Louisiana · R01 · FY2011 · AI
Antibacterial Host Defense
$567,825Robert Munford · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Quantiferon Gold Test for Detecting TB Infection in HIV/AIDS Patients in Brazil
$567,810Jonathan E Golub · Johns Hopkins University · R01 · FY2015 · AI
Role of IL-17 in Protective Vaccine-induced Immune Responses Against Tuberculosis
$567,793Shabaana A. Khader · University Of Chicago · R01 · FY2022 · HL
Targeting trained immunity and Th1/Th17 axis with combination adjuvants
$567,749Shabaana A. Khader · Washington University · U01 · FY2022 · AI